The annual meeting of ENITEC, the European Network for Personalised Endometrial Cancer Treatment, was held in Barcelona from 6th to 7th March. This year, the event was organised by the biomedical research group in gynaecology at the Vall d'Hebron Research Institute (VHIR), together with the group of Dr. Gema Moreno (MD Anderson Cancer Center Foundation, Autonomous University of Madrid) and Dr. Miguel Abal and Laura Muinelo (Health Research Institute of Santiago de Compostela). This meeting, sponsored by the European Society of Gynecological Oncology (ESGO), CIBER, Roche, Palex and GSK, brought together more than 60 researchers with complementary profiles (gynaecologists, pathologists, biomedical scientists, etc.) from all over the continent to share the latest developments in research into endometrial cancer, the most common gynaecological tumour.

During the meeting, advances were presented that allow new non-invasive diagnostic tools, the identification of risk groups based on molecular and imaging parameters, and new preclinical models to evaluate the effectiveness of treatments, among others. The meeting included a lecture by Dr. Xavier Maties-Guiu, president-elect of the European Society of Pathology and head of the Anatomical Pathology services of the Bellvitge and Arnau de Vilanova University Hospitals, who gave an overview of the major scientific and clinical changes currently being experienced in the field of endometrial cancer.

The ENITEC Network was founded in 2012 with the aim of bringing together researchers from different disciplines (gynaecologists, radiologists, pathologists, etc.), but all working in endometrial cancer research. The institution places special emphasis on integrating molecular studies to improve and personalise treatments and diagnoses. From its inception to date, more than 130 researchers from over 17 different countries have participated in its initiatives.